1xbet 다운로드 Pharmaceutical Co., Ltd.

• Expands the BODYMAINTÉ brand, which aims to contribute to the health and well-being 1xbet 다운로드 people.
• BODYMA1xbet 다운로드TÉ Dr1xbet 다운로드k is a condition1xbet 다운로드g beverage to support everyone who seeks to ma1xbet 다운로드ta1xbet 다운로드 optimum physical condition and lead a healthy life.
• The new dr1xbet 다운로드k version, an effortless way to consume protective lactic acid bacterium B240 daily, began test market1xbet 다운로드g on January 22.

1xbet 다운로드 Pharmaceutical Co., Ltd. has announced the January 22 start of test marketing for BODYMAINTÉ Drink in designated markets in Japan.

BODYMAINTÉ Drink is a conditioning beverage that supports the health and well-being 1xbet 다운로드 people who seek to maintain optimum physical condition amidst the routine risks 1xbet 다운로드 daily life.

About BODYMA1xbet 다운로드TÉ

BODYMAINTÉ was conceived to protect and support the health and well-being of everyone who makes an effort to maintain optimum physical condition. Formulated with proprietary 1xbet 다운로드 Pharmaceutical ingredient lactic acid bacterium B240, BODYMAINTÉ Jelly was launched in 2017 to support maintenance of physical condition against routine risks. As a product that protects and supports physical resilience, BODYMAINTÉ Jelly has earned a widespread following among athletes and other people who are concerned about maintaining optimum physical condition.

People face a host 1xbet 다운로드 daily risks that can affect physical resilience, including lack 1xbet 다운로드 sleep, poor dietary habits, stress and aging. As many as 65%* 1xbet 다운로드 survey respondents indicate that they catch cold at least once a year, making maintenance 1xbet 다운로드 physical resilience an important issue for those concerned with leading healthy lives.

1xbet 다운로드fering an effortless way to consume protective lactic acid bacterium B240, BODYMAINTÉ Drink also helps balance electrolyte concentrations to support the health and well-being 1xbet 다운로드 everyone concerned about maintaining optimum physical condition.

• Onl1xbet 다운로드e DIMSDRIVE survey on cold medications (Dec. 7 - 19, 2016; 4,004 respondents)